News
Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
Lilly executives have touted the once-daily pill, known as orforglipron, as a cheaper alternative to recently-popular obesity injections like its Zepbound offering or Novo’s Wegovy. Both of the medications are currently the main powerhouses of the obesity drug market, which is anticipated to surge to $150 billion in value early in the next decade.
Lilly's Weight Loss Pill Falls Short of Novo's Wegovy in Key Study
Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy. Despite the results, Lilly plans to seek global approval, highlighting the pill's potential for convenience and its heart health benefits.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Clinical Trials Arena on MSN17h
Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight lossOrforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback